CardiaMetrics will take part in FÊNO 2026, the Festival of Normandy Excellence, from October 16 to 18 at the Caen Exhibition Centre.

This year’s edition will be an opportunity for us to introduce CardiaMetrics to the general public, while also highlighting two partners that play an important role in our development: Caen University Hospital and Normandie Incubation.

Saturday, October 17 with Caen University Hospital

📅 Saturday, October 17
🕑 2:00 PM
📍 “À toutes jambes” area – stand ATJ01-10

On Saturday, we will join the teams from Caen University Hospital, with whom CardiaMetrics is currently conducting its first clinical study.

This collaboration contributes to the clinical and technical validation of our approach and represents an important step in the development of CardiaMetrics.

At FÊNO, we will give a presentation and live demonstration of our technology, followed by a Q&A session with the audience. It will be an opportunity to discover our project in a concrete way and to better understand how a medical innovation is developed in close collaboration with hospital teams.

👉 Discover Caen University Hospital

Sunday, October 18 with Normandie Incubation

📅 Sunday, October 18 – morning
📍 “À toutes jambes” area – stand ATJ01-03

On Sunday morning, CardiaMetrics will be present alongside Normandie Incubation, which supports us in structuring and accelerating our development.

Through the NormanDeepTech program and its network, Normandie Incubation helps CardiaMetrics navigate the different stages required to grow a deeptech startup and turn scientific innovation into a structured business project.

We will mainly offer technology demonstrations and answer visitors’ questions about our journey, our technology, and the challenges involved in developing a medtech company.

👉 Discover CardiaMetrics on the Normandie Incubation website

🎥 Watch the interview with Thibault Parmentier produced by Normandie Incubation

👉 Read our previous article about this support

Two Meetings, Two Essential Dimensions of Our Development

These two highlights reflect the way CardiaMetrics is growing: with clinical partners who contribute to evaluating our technology, and with innovation partners who support the company’s growth.

We are pleased to share these collaborations with the FÊNO audience and to show how the Normandy ecosystem is making a concrete contribution to the development of deeptech health projects.

📅 FÊNO 2026 — October 16 to 18
📍 Caen Exhibition Centre

👉 All practical information about FÊNO

We look forward to seeing you there!

#CardiaMetrics #FENO2026 #Normandy #CHUCaen #NormandieIncubation #Deeptech #MedTech #Innovation #Health

CardiaMetrics is pleased to announce its participation in BIG 2026, Bpifrance’s annual gathering for entrepreneurs, innovators and investors, taking place on October 8, 2026 at the Accor Arena in Paris.

As part of the Deeptech Seed program, CardiaMetrics has been selected among 12 startups invited to present their projects during the session “Deeptech Seed: Meet the 12 Startups from the Program.”

Cindy Michel to Present CardiaMetrics on the Deeptech Stage

At 2:19 PM, Cindy Michel, co-founder and Chief Scientific Officer of CardiaMetrics, will take the stage at Les Voix de l’Innovation – La Deeptech.

In a short pitch, she will present CardiaMetrics’ vision for advancing heart failure monitoring through the combination of physiological signals, medical-device innovation and artificial intelligence.

The session will bring together the 12 Deeptech Seed startups in a dynamic format combining pitches and questions from a panel of investors.

Connecting With the Deeptech Ecosystem

BIG is one of France’s major gatherings for entrepreneurship and innovation, bringing together founders, researchers, investors, corporates and institutions at the Accor Arena for a full day of talks, workshops and networking.

For CardiaMetrics, this participation is another opportunity to share our progress, connect with the French deeptech ecosystem and continue the conversations initiated through the Bpifrance Deeptech Seed program.

📅 October 8, 2026
🕑 2:19 PM
📍 Accor Arena, Paris
🎤 Les Voix de l’Innovation – La Deeptech

👉 Discover the Deeptech Seed session at BIG 2026

👉 Register for BIG 2026

We look forward to seeing you in Paris!

#BIG2026 #Deeptech #MedTech #Innovation #Bpifrance #HeartFailure #Cardiology #DigitalHealth #CardiaMetrics

CardiaMetrics is pleased to be featured by Normandie Incubation in a new article and video interview exploring our journey, our roots in Normandy, and the milestones supporting the company’s growth.

In the interview, Thibault Parmentier, President and co-founder of CardiaMetrics, discusses the role played by the Normandy innovation ecosystem in our development, from the NormanDeepTech program to the support of PUI Normandie, Région Normandie and AD Normandie. He also looks back on recent milestones including our selection as a 2026 i-Lab laureate and the next stages in CardiaMetrics’ development.

Growing Within the Normandy Ecosystem

Since establishing its headquarters in Caen, CardiaMetrics has benefited from an ecosystem combining clinical expertise, innovation support and close connections with regional partners.

Normandie Incubation has been part of this journey, helping the team structure priorities, challenge key decisions and access the right expertise as the company moves forward.

Building Momentum

The feature comes at an important time for CardiaMetrics, with recent scientific, clinical and corporate milestones reflecting the progress made by the team and the strength of the network supporting the company.

We are grateful to Normandie Incubation and the broader Normandy innovation ecosystem for their continued support.

👉 Read the full article and watch the interview on Normandie Incubation

🎥 Watch the interview on YouTube:

#CardiaMetrics #NormandieIncubation #NormanDeepTech #Deeptech #MedTech #Innovation #Normandie

CardiaMetrics is proud to announce that it has been named a 2026 laureate of the i-Lab Innovation Competition, one of France’s leading programs supporting the creation and development of innovative technology companies.

The announcement was made during the 2026 State Innovation Competitions ceremony held in Paris on September 16. This year, 69 i-Lab projects were selected from 569 applications, including 10 Grands Prix. The competition represents €25 million in total support for this year’s laureates. View the official 2026 laureates announcement

Supported by France 2030 and operated by Bpifrance on behalf of the French State, i-Lab supports research and development projects aimed at bringing innovative technological products, processes and services closer to market. Selected projects can benefit from significant financial support, together with dedicated guidance throughout their development. Learn more about the i-Lab Innovation Competition

For CardiaMetrics, this distinction recognizes the scientific and technological foundations of our approach to heart failure monitoring and will support the next stage of development of our solution.

Addressing a Major Challenge in Heart Failure Care

Heart failure is a chronic condition characterized by periods of relative stability interrupted by episodes of decompensation. These episodes can lead to hospitalization and contribute to progressive deterioration in patients’ health and quality of life.

One of the major challenges in heart failure care is therefore not only responding to decompensation once symptoms become apparent, but identifying physiological changes early enough to give care teams more time to act.

Today, remote monitoring often relies on indicators such as symptoms, weight measurements and patient questionnaires. While valuable, these indicators can appear relatively late in the deterioration process and depend on regular patient participation.

CardiaMetrics is developing a different approach: providing healthcare professionals with earlier and clinically relevant physiological information to help maintain patients in a stable condition over time.

Combining Medical Devices, Physiological Signals and Artificial Intelligence

The CardiaMetrics approach is built around three complementary areas of innovation.

The first is a miniaturized and autonomous subcutaneous sensor designed to collect physiological signals automatically over time, without requiring daily measurements from the patient.

The second is MERCURE, our proprietary approach combining physiological signals and machine learning to estimate hemodynamic information associated with cardiac filling pressures.

Preliminary work presented by CardiaMetrics at Technology and Heart Failure Therapeutics 2026 in Boston demonstrated the feasibility of this approach. These early findings were encouraging and now require validation in larger prospective cohorts.

Read about CardiaMetrics’ first scientific results presented at THT 2026

The third is an innovation in the way these data can be integrated into the care pathway. The objective is not simply to generate additional measurements, but to provide clinically meaningful information that can support healthcare professionals in assessing patient status over time and making therapeutic decisions.

Together, these innovations reflect our vision of remote monitoring: reliable physiological information, collected with minimal burden for the patient and translated into actionable insights for care teams.

Supporting the Next Stage of Clinical Development

The i-Lab distinction will help CardiaMetrics accelerate the next stage of its scientific and clinical development.

Following our initial proof-of-concept work, the program will support further validation of our technology, including evaluation of the subcutaneous device, continued development of our physiological models, and work toward integrating these measurements into real-world clinical practice.

This is an essential step. In remote monitoring, generating a physiological measurement is only one part of the challenge. That information must also be reliable, interpretable and useful in clinical practice.

Readers interested in the broader scientific foundations of CardiaMetrics’ work can also explore our ongoing clinical research and innovation activities.

Discover CardiaMetrics Research & Innovation

Moving Toward More Proactive Heart Failure Care

At CardiaMetrics, our ambition goes beyond detecting an impending hospitalization.

We aim to contribute to a shift from reactive monitoring toward a more proactive approach to heart failure care — providing relevant information early enough to support clinical intervention and help maintain patients in a stable condition for longer.

This vision is at the heart of our work: combining automated physiological data collection with clinically meaningful insights to support more personalized and efficient patient follow-up.

This approach also reflects some of the key discussions we recently shared following Heart Failure 2026, where the growing role of clinically actionable remote monitoring was central to exchanges with the heart failure community.

Read our key insights from Heart Failure 2026

A Recognition of a Collective Effort

Being selected as an i-Lab laureate represents an important milestone for CardiaMetrics and recognition of the work carried out by our entire team.

Since its creation, i-Lab has become a recognized program within the French deeptech ecosystem, supporting innovative companies born from research and helping them advance their technological development. Nearly 5,000 laureates have been recognized through the State Innovation Competitions since 1999.

We would like to thank France 2030, Bpifrance, the members of the i-Lab jury, and all the clinicians, researchers, institutions and partners who have contributed to CardiaMetrics’ journey.

This distinction marks another important step in our mission: turning physiological data into actionable information to support more proactive and personalized heart failure care.

#iLab #France2030 #Bpifrance #Deeptech #HeartFailure #Cardiology #MedTech #DigitalHealth #Innovation #CardiaMetrics

CardiaMetrics is proud to announce that we have been selected to join the Deeptech Accelerator program led by Bpifrance, becoming the only startup from Normandy to be part of this prestigious cohort.

This recognition marks an important milestone in our journey to transform heart failure care through innovative remote monitoring technologies.

Read the full media coverage by Ouest-France

Recognition of Our Deeptech Vision

The Deeptech Accelerator supports high-impact startups developing breakthrough technologies grounded in strong scientific foundations. CardiaMetrics’ selection reflects the relevance of our approach combining advanced sensing technologies, machine learning, and clinical research to improve the management of heart failure patients.

Being part of this program will help us structure our growth, strengthen our industrial strategy, and accelerate clinical development, while benefiting from mentorship, funding support, and access to a powerful innovation ecosystem.

Strengthening Our Development Roadmap

Since our creation, CardiaMetrics has focused on building a clinically driven innovation, working closely with healthcare professionals and research partners to validate the safety and performance of our technology.

Participation in the Deeptech Accelerator will enable us to:

• Accelerate product development and regulatory readiness
• Expand clinical evidence generation
• Reinforce our strategic positioning in the heart failure monitoring market
• Scale our impact across France and internationally

A Collective Achievement

This milestone reflects the dedication of our growing team, the trust of our investors, and the support of our clinical partners.

We are honored to contribute to the dynamism of the Normandy deeptech ecosystem and to help position French innovation at the forefront of cardiovascular care.

Stay tuned for more updates as we continue to advance toward the next stages of clinical validation and market access.